Navigation Links
Tranzbyte Corporation Acquires the Exclusive Right to Market Low-Cost, Innovative MRI machines in North and South America
Date:9/11/2012

company expects to continue its plan to acquire, hold, or spin out successful divisions in what has been described in previous news releases as "dividend farming,"  Companies that qualify and decide to become public on their own will agree to carve out shares for Tranzbyte and their ERBB shareholders.

Earlier this year, Tranzbyte acquired ProximaRF – a leading-edge company that produces a line of products supporting leading-edge RFID technology.

Tranzbyte also houses the company's 9-year-old technology division which is actively engaged in the sale of its optical media enhancement products to potential customers in the US and Asia. Products in the Tranzbyte division include FLASHAlbum™ and FlixStix -- technologies that enable distributors of optical media (CDs, DVDs, etc.) to consolidate the best features of each medium onto a single content-protected USB flash drive.

NOTES ABOUT FORWARD-LOOKING STATEMENTS

Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company's Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expecta
'/>"/>

SOURCE Tranzbyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. American Pacific Corporation Completes Redemption Of $40 Million Of Senior Notes
2. NextDocs Corporation Announces Trial Exchange, a Clinical Portal Designed Specifically for Clinical Trial Sites and Integrated with eTMF
3. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
4. Faruqi & Faruqi, LLP is Investigating AmerisourceBergen Corporation on Behalf of its Shareholders
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
7. Sigma-Aldrich Corporation To Present At Upcoming Investor Conferences
8. Luminex Corporation Recognized as Best Technology Company in Austin
9. VLST Corporation Announces In-licensing Agreement with Pfizer for Anti-CD40 Monoclonal Antibody
10. MGC Diagnostics Corporation Completes Sale of New Leaf Business Assets to Life Time - The Healthy Way of Life Company
11. MGC Diagnostics Corporation Reports Third Quarter Fiscal Year 2012 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- Today leading ... all new data ranking Pharmaceutical web sites for usability, ... Sciences, User Experience Cloud platform, which compares how people ... on the web. The top three performers ... convert people overall. The bottom performers have usability problems, ...
(Date:6/19/2013)... 19, 2013 Today MedeAnalytics, a leading ... next-generation of its Employer Group and Individual ... to provide their employer groups an intuitive and ... and prescription drug claims, network utilization, and overall ... ) "Employer Group and Individual ...
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... Bristol-Myers Squibb, Company and Gilead Sciences, ... -, PRINCETON, N.J. and FOSTER CITY, Calif., ... BMY ) and Gilead Sciences, Inc.,(Nasdaq: GILD ... ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300,mg) ...
... to Compare Genous vs. Drug-Eluting and Bare ... ... Enrollment in the,randomized TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered ... in April, according to Robbert de Winter, M.D., Ph.D.,principal investigator and ...
Cached Medicine Technology:Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2
(Date:6/19/2013)... LOS ANGELES (June 19, 2013) In what is ... with the most common form of hereditary dystonia ... experts in deep brain stimulation report good success ... director of the Movement Disorders Program at Cedars-Sinai Medical ... chief of the Division of Neurosurgery at Beth Israel ...
(Date:6/19/2013)... of three important studies have been published in the ... the Congress of Neurological Surgeons . The ... , a part of Wolters Kluwer Health . ... artificial neural networks (ANNs) may improve the ability to ... study in the June Neurosurgery supports increased ...
(Date:6/19/2013)... Children had half as many emergency department ... hours on five or more days a week, according ... Mott Children,s Hospital and Johns Hopkins University. , The ... The Journal of Pediatrics and will be presented ... are an important step in understanding where primary care ...
(Date:6/19/2013)... Spanish . ... goes by the name of the 10/90 gap: only 10 ... that accounted for 90 per cent of the global disease ... for Neglected Diseases initiative (DNDi) came into being in 2003. ... granted the BBVA Foundation Frontiers of Knowledge Award in the ...
(Date:6/19/2013)... are increasingly common on college campuses, but are ... up"? A new study by researchers with The ... published online by the Archives of Sexual ... behaviors associated with sexual hookups, particularly among first-year ... negative emotional and physical health outcomes as a ...
Breaking Medicine News(10 mins):Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 2Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 3Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 4Health News:DNDi receives the BBVA Foundation Frontiers of Knowledge Award in Development Cooperation 5Health News:Why are some college students more likely to 'hook up'? 2
... many biological processes also may play a role in memory, ... California and the National Institute on Aging at the National ... the Journal of Neuroscience, agree with research by ... Both studies found that mice lacking the protein SIRT1 exhibited ...
... in specific brain regions in female patients with irritable bowel ... the abdomen, along with diarrhea, constipation or both. ... University, the study appears in the July issue of the ... that IBS is associated with both decreases and increases in ...
... HealthDay Reporter , WEDNESDAY, July 21 (HealthDay News) ... be candidates for vaginal birth in future pregnancies, say ... Gynecologists. "These guidelines emphasize again that a trial ... most women," said one of the authors of the ...
... 2010 (Oakland, Calif.) A total joint replacement registry ... patient safety, quality of care, cost-effectiveness and research, according ... editions of Clinical Orthopedics and Related Research , ... Surgeons. Kaiser Permanente,s Total Joint Replacement Registry ...
... Against the backdrop of some of the globe,s fastest ... a report launched today at the XVIII International AIDS ... a new model for scaling up treatment and prevention ... The report, "Prevention and Treatment of HIV/AIDS amongst Drug ...
... July 22, 2010 -- Child abuse is a serious problem ... United States alone. The American Academy of Pediatrics and ... abuse into four categories including neglect, physical abuse, sexual abuse, ... includes the abusive use of drugs on children. A ...
Cached Medicine News:Health News:SIRT1 gene important for memory 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 3Health News:Vaginal Delivery May Be OK After C-Section 2Health News:Vaginal Delivery May Be OK After C-Section 3Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 2Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 3Health News:New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: 'Seek, test, treat and retain' 4Health News:The malicious use of pharmaceuticals: An under-recognized form of child abuse 2
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
... is an Auto Refractor/Keratometer with ... refinement. Electronic elevation, automatic alignment, ... accuracy and all the other ... Marco Automatic Refractors/Keratometer famous, make ...
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Medicine Products: